Interestingly, efforts to establish reliable biomarkers for PCa diagnosis and progression have prompted researchers to investigate serum-based markers, including SIRT7, with a comparative study evaluating the serum levels of SIRT7 alongside other biomarkers, such as Pentraxin-3 and Fetuin-A, in patients with PCa and benign prostatic hyperplasia [172]. Here, SIRT7 is linked to benign prostatic hyperplasia.